SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board:
Last Post: 12/2/2016 1:48:08 PM - Followers: 140 - Board type: Free - Posts Today: 3


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
OXIS News: Securities Registration Statement (s-1/a) 11/21/2016 04:21:32 PM
OXIS News: Quarterly Report (10-q) 11/14/2016 05:44:58 PM
OXIS News: Securities Registration Statement (s-1/a) 10/31/2016 09:25:03 AM
OXIS News: Securities Registration Statement (s-1/a) 10/03/2016 06:06:05 AM
OXIS News: Securities Registration Statement (s-1/a) 08/25/2016 06:01:53 AM
#8300   you losers get funding yet? Dip66 12/02/16 01:48:08 PM
#8299   Not going to go that low, not even Gibba 12/02/16 11:08:55 AM
#8298   I hope that is a leveling point. .05 Fibanotch 12/02/16 11:05:22 AM
#8297   No, not yet.... mrcraigo 12/01/16 01:24:35 PM
#8296   did we hit .05 cents yet???????? Fibanotch 11/30/16 09:28:50 AM
#8295   nice pop today hopefully news on way Dip66 11/28/16 04:06:57 PM
#8294   I see it's been trending back down...needs to CashBowski 11/22/16 02:40:51 PM
#8293   More news this week. IMO Gibba 11/15/16 10:40:10 AM
#8292   I agree Cbdpotential 11/14/16 04:38:24 PM
#8291   There is Enormous Potential Here- IMO Gibba 11/14/16 04:14:59 PM
#8290   What is the connection between oxis and mcet? braveheart63 11/14/16 02:35:25 PM
#8289   Def worth keeping an eye on imo Cbdpotential 11/14/16 01:40:35 PM
#8288   Future reverse split is false. Gibba 11/14/16 11:46:28 AM
#8287   Questionable past but good news real soon. IMO Gibba 11/14/16 11:13:08 AM
#8286   Scammers brandao 11/13/16 02:29:39 PM
#8285   I couldn't resist. I bought more today. Something Gibba 11/10/16 11:52:04 PM
#8284   Sorry wrong site. WhatNestEgg 11/10/16 10:19:03 PM
#8283   Wasn't this company at $2.00 a share like Dip66 11/10/16 10:18:08 PM
#8282   I could not find info about RS. They jimbosskow 11/10/16 06:00:50 PM
#8281   Good grief. Pre-RS $.00032. My God. How's ole Rapture2020 11/10/16 05:53:49 PM
#8280   here comes that RS i warned you about animaljive 11/10/16 04:21:47 PM
#8279   Why the drop today? willlbone 11/10/16 03:37:02 PM
#8276   Thank you kihmjc7. It is so quiet on jimbosskow 11/08/16 05:42:49 PM
#8275   What a nice run today. jimbosskow 11/08/16 05:36:13 PM
#8274   I would agree :-) Gibba 11/08/16 03:02:22 PM
#8273   Somebody knows something here. This is not kihmjc7 11/08/16 01:46:11 PM
#8272   Feeling good about the near future - Gibba 11/08/16 12:55:39 PM
#8271   OXIS & MCET the perfect marriage to the Dip66 11/08/16 11:18:26 AM
#8270   After looking, my best guess on the institutional kihmjc7 11/08/16 10:22:10 AM
#8269   Some serious buying going on here today. kihmjc7 11/08/16 09:50:26 AM
#8268   She's runnin' again today! kihmjc7 11/08/16 09:33:32 AM
#8267   No sure yet, but similarly saw through my kihmjc7 11/07/16 09:30:08 PM
#8266   Hey there, do you happen to know what jimbosskow 11/07/16 06:23:37 PM
#8265   Nice gains over the past couple of sessions kihmjc7 11/07/16 09:59:04 AM
#8264   Hallo anyone?!? Echo echo cho ho ooo... lol jimbosskow 11/05/16 01:11:18 PM
#8263   OXIS' TriKE Cancer-Fighting Platform Receives Favorable News Coverage TPX 11/04/16 09:18:06 PM
#8262   Hey guys, jimbosskow 11/04/16 06:04:39 PM
#8261   Lol. Definitely...load the boat man. Good call. Halks1122 11/04/16 05:36:53 PM
#8260   Good entry point? This company is down to Dip66 11/04/16 08:48:47 AM
#8259   Good entry point here IMO kihmjc7 11/03/16 12:36:58 PM
#8258   I wish I was wrong....05 Fibanotch 11/03/16 10:41:11 AM
#8257   Huh? All I know is oxis is done djmurdock 11/02/16 04:02:37 PM
#8255   I got burned by this one....this POS is djmurdock 11/01/16 01:49:14 PM
#8254   .14 was the level we were hoping to CashBowski 10/29/16 12:44:06 PM
#8253   ....These kinda of stocks only pop once in Fibanotch 10/26/16 09:53:16 AM
#8252   many old timers are starting bontooth 10/24/16 10:51:44 PM
#8251   Oxis you guys still in business or what? Dip66 10/24/16 01:08:20 PM
#8250   I'd bet ya the downtrend continues, but I Halks1122 10/14/16 11:48:03 AM
#8249   We're not far off. We'll know in the CashBowski 10/13/16 06:57:02 PM
#8248   o Fibanotch 10/13/16 02:30:36 PM